Epizyme Financials

EPZMDelisted Stock  USD 1.47  0.00  0.00%   
Based on the measurements of operating efficiency obtained from Epizyme's historical financial statements, Epizyme is not in a good financial situation at the moment. It has a very high risk of going through financial straits in May.
With this module, you can analyze Epizyme financials for your investing period. You should be able to track the changes in Epizyme individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  
Understanding current and past Epizyme Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Epizyme's financial statements are interrelated, with each one affecting the others. For example, an increase in Epizyme's assets may result in an increase in income on the income statement.
The data published in Epizyme's official financial statements usually reflect Epizyme's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Epizyme. For example, before you start analyzing numbers published by Epizyme accountants, it's critical to develop an understanding of what Epizyme's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Epizyme's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Epizyme's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Epizyme's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Epizyme. Please utilize our Beneish M Score to check the likelihood of Epizyme's management manipulating its earnings.

Epizyme Stock Summary

Epizyme competes with JD Sports, Funko, Playa Hotels, Sonos, and Amkor Technology. Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Epizyme operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 250 people.
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS29428V1044
Business Address400 Technology Square,
SectorHealthcare
IndustryBiotechnology
BenchmarkNYSE Composite
Websitewww.epizyme.com
Phone617 229 5872
CurrencyUSD - US Dollar
You should never invest in Epizyme without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Epizyme Stock, because this is throwing your money away. Analyzing the key information contained in Epizyme's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Epizyme Key Financial Ratios

Generally speaking, Epizyme's financial ratios allow both analysts and investors to convert raw data from Epizyme's financial statements into concise, actionable information that can be used to evaluate the performance of Epizyme over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Epizyme reports annually and quarterly.

Epizyme Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Epizyme's current stock value. Our valuation model uses many indicators to compare Epizyme value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Epizyme competition to find correlations between indicators driving Epizyme's intrinsic value. More Info.
Epizyme is one of the top stocks in return on equity category among related companies. It is one of the top stocks in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Epizyme by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Epizyme's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Epizyme's earnings, one of the primary drivers of an investment's value.

Epizyme Market Pulse

 Quote1.47
 Change(%) 0.00  
 Change0.00 
 Open1.47
 Low1.47
 High1.47
 Volume0
 ExchangeNASDAQ

About Epizyme Financials

What exactly are Epizyme Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Epizyme's income statement, its balance sheet, and the statement of cash flows. Potential Epizyme investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Epizyme investors may use each financial statement separately, they are all related. The changes in Epizyme's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Epizyme's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze Epizyme Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Epizyme is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Epizyme has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if Epizyme's financials are consistent with your investment objective using the following steps:
  • Review Epizyme's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand Epizyme's liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare Epizyme's financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Epizyme's stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

Epizyme Thematic Clasifications

Epizyme is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
Cancer FightersView
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas

Epizyme April 19, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Epizyme help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Epizyme. We use our internally-developed statistical techniques to arrive at the intrinsic value of Epizyme based on widely used predictive technical indicators. In general, we focus on analyzing Epizyme Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Epizyme's daily price indicators and compare them against related drivers.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the Epizyme information on this page should be used as a complementary analysis to other Epizyme's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.

Other Consideration for investing in Epizyme Stock

If you are still planning to invest in Epizyme check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Epizyme's history and understand the potential risks before investing.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Transaction History
View history of all your transactions and understand their impact on performance
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites